T0	Participants 43 92	male patients with diffuse large B-cell lymphoma.
T1	Participants 127 138	multicentre
T2	Participants 364 471	321 patients [161 randomized to the treatment group (TG), 160 to the observation group (OG)], 295 data sets
T3	Participants 658 674	(DLBCL) subgroup
T4	Participants 787 825	in male patients of the DLBCL subgroup
T5	Participants 1406 1431	survival in male patients